---
title: "Recursion Pharmaceuticals Announces New Clinical Data Readout for REC-4881 in Familial Adenomatous Polyposis"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/268098083.md"
description: "Recursion Pharmaceuticals will present new clinical data from the TUPELO Phase 1b/2 trial of REC-4881 for Familial Adenomatous Polyposis on December 8, 2025. The webinar will include safety and efficacy results, featuring presentations by company leaders and external experts. The results have not been disclosed yet."
datetime: "2025-12-01T13:30:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/268098083.md)
  - [en](https://longbridge.com/en/news/268098083.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/268098083.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/268098083.md) | [繁體中文](https://longbridge.com/zh-HK/news/268098083.md)


# Recursion Pharmaceuticals Announces New Clinical Data Readout for REC-4881 in Familial Adenomatous Polyposis

Recursion Pharmaceuticals Inc. has announced that it will present new clinical data from the ongoing TUPELO Phase 1b/2 trial of REC-4881, an allosteric MEK1/2 inhibitor, in patients with Familial Adenomatous Polyposis (FAP). The updated safety and efficacy results will be shared during a company-hosted webinar scheduled for December 8, 2025. The webinar will feature presentations by Recursion’s executive and clinical leadership, as well as external experts. The results have not yet been presented and will be disclosed during the upcoming event. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recursion Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9594197-en) on December 01, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)

### Related Stocks

- [Recursion Pharmaceuticals, Inc. (RXRX.US)](https://longbridge.com/en/quote/RXRX.US.md)

## Related News & Research

- [Recursion Pharma Q4 revenue tops eatimates, helped by Sanofi payments](https://longbridge.com/en/news/276880192.md)
- [Recursion Reports Positive Phase 2 Results for REC-4881 in Familial Adenomatous Polyposis](https://longbridge.com/en/news/268948109.md)
- [Does NewMarket’s Boardroom Shuffle and Dividend Reaffirmation Clarify Its Petroleum Additives Strategy for NEU?](https://longbridge.com/en/news/277799221.md)
- [AutoNation, Inc. $AN Shares Sold by South Dakota Investment Council](https://longbridge.com/en/news/277624155.md)
- [BridgeBio Oncology Touts “Best in RAS” Pipeline, Highlights BBO-8520 Response and Combo Tolerability](https://longbridge.com/en/news/276975538.md)